Product Name: Polydeoxyribonucleotide; PDRN

Other Name:DEOXYRIBONUCLEIC ACID, SODIUM SALT FROM SALMON TESTES

Appearance: White powder

Purity: 99.8%

PDRN Origin and First Discovery (1986)

In 1986, Italian scientists first characterized PDRN (polydeoxyribonucleotide), confirming its core pharmacological activity in activating cell 

proliferation and promoting tissue repair, thereby laying the foundation for regenerative medicine. 

In 1994, Placentex® (developed by Mastelli in Italy), the world's first PDRN drug, was launched. It was initially approved for connective 

tissue repair and prevention of pathological scars, marking the beginning of its clinical application era.

wound treatment: First approved in Italy (2003)

In 2003, Italy became the first country in the world to officially approve PDRN for wound healing, establishing itself as the pioneer in 

recognizing PDRN as a therapeutic agent for chronic wounds. 

Approved indications: refractory wounds such as diabetic foot ulcers, ischemic ulcers, and pressure injuries; significantly reduces healing time, 

lowers infection risk, and shortens hospitalization duration. 

Italian pharmaceutical companies (Mastelli and Promoitalia) have achieved commercial production, solidifying Europe's core position 

in PDRN regenerative medicine. 

◵ Arthritis/Osteoarthritis: Italian clinical pioneer (after 2010)

Since 2010, Italy has conducted clinical studies on PDRN for knee osteoarthritis (OA), confirming its pivotal effects in anti-inflammatory action, 

cartilage repair, and improvement of joint function.

In 2013, Italian researchers Di Nicola and Pierpaoli published a study demonstrating that PDRN regenerative gel significantly alleviated joint pain, 

improved range of motion, and repaired cartilage damage, marking the world's first clinical report on PDRN for arthritis. 

Italy is the birthplace of the PDRN joint injection combined with hyaluronic acid (HA) therapy. Clinical data demonstrate: 16% improvement in pain relief, 

22% enhancement in function, and 18% increase in cartilage thickness, with superior efficacy compared to HA monotherapy. 

Italian Original and Global Premiere: PDRN's discovery, drug approval, wound treatment certification, and clinical applications for arthritis all originated 

in Italy, establishing it as a benchmark in the field of regenerative medicine. 

Over 30 years of clinical validation: Since 1994, more than one million cases worldwide have confirmed the safety, efficacy, and absence of rejection 

associated with PDRN, establishing it as the gold standard for wound repair and arthritis treatment. 

Polydeoxyribonucleotide (PDRN) is a reliable cell growth active substance and a mixture of DNA. It is extracted from salmon sperm,DNA and derived 

from controlled purification and sterilization process.

★Is Polydeoxyribonucleotide suitable for post-procedure skincare products?

Yes, PDRN is widely used in post-procedure skincare formulations due to its ability to support skin recovery and reduce visible signs of irritation. 

It is often included in products designed for use after aesthetic treatments.

★What are the key benefits of Polydeoxyribonucleotide in skincare formulations?

PDRN offers multiple benefits, including improved skin elasticity, enhanced hydration, reduced appearance of fine lines, and support for skin barrier repair. 

These combined effects contribute to healthier and more resilient skin.

MOQ: 500grams

Package: 500grams/bottle, 10 bottle per carton.

Storage：Store in a cool 2-8 degree, dry place and keep tightly sealed.